Current Press Releases
Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)
- Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry
- Based on a novel mechanism of action involving IL-32 and directly implicated in CKD, discovered in pre-clinical studies led by Dr. Justin Chun
- The Company has filed both composition and method of use patents relating to the CKD platform.
- The Arch CKD program will be led by Dr. Justin Chun, who joins the Company as a Principal Scientist
- CKD is largely an unmet medical need, currently affecting more than 800 million people ...
Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury
- First patient successfully completes dosing at Toronto General Hospital
- St. Michael’s Hospital is expected to be the next Canadian clinical site activated
- Arch is looking for additional clinical sites in North America to join the trial
Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)
TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the investigator-led Phase II trial titled “Prevention Of NephroToxin Induced Acute Kidney Injury with Cilastatin” (PONTIAK) has commenced patient recruitment at its primary clinical sites in Alberta, Canada. The Phase II PONTIAK study aims to evaluate the efficacy of cilastatin in preventing AKI associated with nephrotoxic pharmaceuticals, which include commonly used drugs such as antibiotics, chemotherapy agents, and imaging dyes, some of which are known to cause ...
